Pietro Roccatagliata

Dr. Pietro Roccatagliata


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
FGFrancesco Giurazza
Francesco Giurazza
PRPietro Roccatagliata
Pietro Roccatagliata
CCClaudio Carrubba
Claudio Carrubba
Fabio CorvinoFabio Corvino
Fabio Corvino
RTRaffaella Tortora
Raffaella Tortora
RNRaffaella Niola
Raffaella Niola
Background/Objectives: Transarterial chemoembolization (TACE) is included in international guidelines for the treatment of hepatocellular carcinoma (HCC), but it is still not a standardized intervention in terms of vector and chemotherapy. This study aims to report on clinical and radiological outcomes of degradable starch microspheres TACE (DSM-TACE) with idarubicin and compare with DSM-TACE with an epirubicin protocol after a single session. Methods: This is a single-center retrospective study analyzing cirrhotic patients affected by HCC in early or intermediate stages. Primary objectives were to assess the safety and efficacy of a single DSM-TACE with 10 mg idarubicin in terms of adverse event (AE) occurrences evaluated via the CTCAE 5.0 system and mRECIST criteria with computed tomography (CT) at 3 months. The secondary purpose was to compare the procedural outcomes with those from patients treated with DSM-TACE with 50 mg epirubicin. Results: Thirty-seven patients were included, 19 treated with idarubicin (IDA group) and 18 with epirubicin (EPI group); demographic data and lesion characteristics were comparable. No major AE (grade ≥ 3) occurred overall. In the IDA group, the minor AE incidence was 52.7%: one patient presented with mild ascites, eight developed hyperbilirubinemia and one leucopenia. At the 3-month CT follow-up, mRECIST criteria reported an overall response rate (ORR) of 63.2% and a disease control rate (DCR) of 84.2%. No statistically significant differences were appreciable comparing both AE occurrence and mRECIST findings with the EPI group (50% minor AE, 77.8% ORR, 88.9% DCR). Conclusions: In this sample of cirrhotic patients with HCC, DSM-TACE with 10 mg idarubicin was safe and effective comparable to DSM-TACE with 50 mg epirubicin.

25 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
PRPietro Roccatagliata
Pietro Roccatagliata
FGFrancesco Giurazza
Francesco Giurazza
ADAndrea Discalzi
Andrea Discalzi
HTHūseyin Saygin Tuna
Hūseyin Saygin Tuna
Fabio CorvinoFabio Corvino
Fabio Corvino
RNRaffaella Niola
Raffaella Niola
Background/Objectives: This study aims to analyze safety and effectiveness of imipenem/cilastatin sodium (IPM/CS) as an off-label embolic agent in acute lower gastrointestinal bleeding (LGIB). Methods: This is a multicentric prospective study including patients treated in emergency with endovascular embolization for acute LGIB. IPM/CS particles were prepared using one vial containing 500 mg/500 mg of IPM/CS in powder diluted with 5 mL of pure iodine contrast agent. Inclusion criteria were: acute bleeding managed with IMP/CS embolization, unfeasible/ineffective endoscopic management, availability of a pre-procedural contrast-enhanced Computed Tomography (CT) scan, pre- and post-procedural blood count, pre- and post-procedural hemodynamic balance evaluation, and follow-up to 30 days. Exclusion criteria were: patients treated in elective conditions, LGIB embolization performed without IMP/CS, IMP/CS adoption after other embolics, incomplete clinical–laboratoristic follow-up, and age < 18 years. Technical success was intended as angiographic disappearance of extravasation or significant reduction/stasis of blood flow to the target; clinical success was considered as hemoglobin values increase and/or stop transfusions and/or hemodynamic restoration. Result: Twenty-one patients were enrolled; bleeding etiologies included angiodysplasia, diverticular disease, gastrointestinal tumor-related bleeding, and post-surgical hemorrhage. Technical success rate was 100%, and clinical success rate at 30 days was 85.7%. Rebleeding occurred in three patients: two managed with surgery and one with coil re-embolization. Neither major and IPM/CS related complications occurred. Conclusions: In this study IPM/CS was a safe and feasible embolic agent in selected patients with acute LGIB; no bowel ischemia occurred during the 30 day follow-up. Future studies with larger samples are required to confirm these findings to include IPM/CS as an off-label alternative embolic agent in LGIB.

5 November 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
FGFrancesco Giurazza
Francesco Giurazza
Fabio CorvinoFabio Corvino
Fabio Corvino
FDFelice D'Antuono
Felice D'Antuono
CCClaudio Carrubba
Claudio Carrubba
PRPietro Roccatagliata
Pietro Roccatagliata
RNRaffaella Niola
Raffaella Niola
Objectives: This study aims to report on radial access for transarterial chemoembolization (TACE), comparing right and left accesses in terms of technical effectiveness, safety, operator radiation exposure, and procedural comfort. Methods: In a single-center prospective design, patients were randomized into two groups according to right (R) or left (L) radial access. Primary endpoints were used to assess the efficacy and safety of radial access to perform liver TACE interventions; secondary endpoints were used to compare procedural comfort and operator radiation exposure. Technical efficacy was intended as procedural accomplishment via sole radial access. Safety was assessed in terms of complication occurrence. Operator radiation exposure was monitored according to dosimeters and beam-on time. Patient and operator procedural comfort was investigated using a visual analog scale. Results: A total of 61 patients (17 women and 44 men; mean age 68.4 years) were enrolled. Group R included 32 patients, and group L had 29; all were affected by hepatocellular carcinoma and treated with palliative or bridge-to-transplant intent. Sixteen (26.2%) had abnormal coagulation function. Technical success did not statistically differ between the two groups (96.8% group R vs. 100% group L). No major complications were recorded. While no differences were detected in terms of radiation exposure values and patient comfort, operators were significantly in favor of the right radial artery. Conclusions: In this sample, both right and left radial access were technically effective and safe, without significant differences in operator radiation exposure and patient comfort; considering significantly higher operator comfort with the right approach, right radial artery could be considered the right radial access for liver TACE interventions.